Ronald de Wit, MD, PhD, on Bladder Cancer: Results From KEYNOTE-057
ESMO 2018 CongressRonald de Wit, MD, PhD, of the University Medical Center Rotterdam, discusses phase II findings on the efficacy of pembrolizumab in Bacillus Calmette Geurin–unresponsive bladder cancer with high risk for disease progression.
Related Videos
Matti S. Aapro, MD, on Advanced Disease: Reducing Use of Futile Treatments
Matti S. Aapro, MD, of the Genolier Cancer Centre, discusses the challenges of avoiding futile treatments and the need to work with patients, integrate palliative care, and m...
Laurence Albiges, MD, PhD, on RCC: Challenging Established Front-Line Treatment
Laurence Albiges, MD, PhD, of Gustave Roussy, discusses data from the global, phase III JAVELIN trial that compared axitinib plus avelumab vs sunitinib, which could lead to a new s...
Nicholas D. James, PhD, MBBS, on Prostate Cancer: Updates From the STAMPEDE Trial
Nicholas D. James, PhD, MBBS, of University Hospitals Birmingham NHS Trust, discusses study findings on treating metastatic castration-sensitive prostate cancer, including results ...
Paolo A. Ascierto, MD, on Melanoma: Acute and Chronic Toxicities
Paolo A. Ascierto, MD, of Istituto Nazionale Tumori–Fondazione Pascale, discusses the breakthroughs in melanoma treatment and the challenges of managing toxicities, especiall...
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy
Lisa A. Carey, MD, of the University of North Carolina, and Sherene Loi, MD, PhD, of the Peter MacCallum Cancer Centre, discuss the phase III IMpassion 130 trial t...
